Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2019 | MPN updates: trial updates, combinations & novel therapies

Ruben Mesa • 7 Dec 2019
ASH 2019
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Fedratinib Interferon Luspatercept Momelotinib Pacritinib Pelabresib Pomalidomide Ruxolitinib

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, highlights the key updates in myeloproliferative neoplasms (MPNs) from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Ruben Mesa

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Ruben Mesa • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Ruben Mesa • 6 Dec 2025
The MPN Journal: a web-based platform developed by patients for patients
1:05
The MPN Journal: a web-based platform developed by patients for patients
Ruben Mesa • 6 Dec 2025
Impact of thrombocytopenia in JAK inhibitor–naive myelofibrosis treated with ruxolitinib
1:12
Impact of thrombocytopenia in JAK inhibitor–naive myelofibrosis treated with ruxolitinib
Ruben Mesa • 6 Dec 2025

Related Videos

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Ruben Mesa • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Ruben Mesa • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Ruben Mesa • 7 Dec 2025
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Ruben Mesa • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals